AtriCure (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has partnered with Baheal Pharmaceutical Group in China to distribute AtriCure’s surgical ablation devices. This new multi-year agreement establishes Baheal as the exclusive distributor for AtriCure, and replaces the company’s previous distributor in China. …

As quoted in the press release:

“We are pleased to have formed this new partnership with Baheal,” said Michael Carrel, AtriCure’s President and Chief Executive Officer. “With Baheal’s stellar reputation, their size and scale, combined with our market-leading devices, we are well positioned to establish a foundation for future growth in China.”
AtriCure has been selling its surgical ablation devices in China for the past 14 years. During that time, several of China’s leading hospitals have adopted AtriCure devices, and in addition, the company expects to pursue new product approvals over the next several years to eventually bring its full portfolio of surgical ablation and left atrial appendage management devices into the market.

Click here to read the full press release.